Artiva Biotherapeutics, Inc. ARTV 深 滬
等待開盤 08-25 09:30:00 美东时间
2.88
+0.110
+3.97%
華盛通- 最 高2.9753
- 今 開2.78
- 成交量 5.01万股
- 最 低 2.78
- 昨 收 2.77
- 總市值 7016.57万
- 52周最高 17.31
- 市盈率 靜 --
- 換手率 0.21%
- 52周最低 1.47
- 委 比 8.26%
- 總股本 2436.31万
- 歷史最高 17.31
- 量 比 0.70
- 振 幅 7.05%
- 歷史最低 1.47
- 每 手 1
- 風險率 1.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
Artiva Biotherapeutics announced progress in its clinical trials for AlloNK® in autoimmune diseases, including treating the first patient in a global basket trial for refractory rheumatoid arthritis, Sjögren’s disease, and systemic sclerosis. Over a dozen patients have been treated across multiple sites. Initial safety and efficacy data are expected by year-end 2025, with clinical response data in the lead indication anticipated in 1H2026. The co...
08-06 20:05
美股大行评级 | GitLab遭多家大行下调目标价！Stifel首予优步"买入"评级，目标价110美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139839943846023169.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Loop Capital：维持Dave & Buster's Enter(PLAY)"买入"评级，目标价从35美元升至46美元</p> <p>• Stifel：维持嘉年华(CCL)"买入"评级，目标价从31美元升至
06-12 09:46
HC Wainwright & Co. Assumes Artiva Biotherapeutics at Buy, Announces Price Target of $12
HC Wainwright & Co. analyst Emily Bodnar assumes Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating and announces Price Target of $12.
06-11 19:03
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
Artiva Biotherapeutics announced its participation in the Jefferies Global Healthcare Conference on June 4, 2025, where management will engage in a fireside chat and investor meetings. The company focuses on developing cell therapies for autoimmune diseases and cancers, with its lead program, AlloNK®, currently in clinical trials. Artiva, headquartered in San Diego, was established in 2019 as a spin-out from GC Cell in South Korea. For more detai...
05-28 20:05
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
Artiva Biotherapeutics Announces Longer-Term Phase 1/2 Data Demonstrating Prolonged Durability For AlloNK In Combination With Rituximab In Patients With B-cell-Non-Hodgkin Lymphoma At The ASGCT 28th Annual Meeting
64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHLMedian duration of
05-14 04:30
Artiva Biotherapeutics Reports Q1 2025 Progress
Artiva Biotherapeutics, Inc. ( ($ARTV) ) has released its Q1 earnings. Here is ...
05-11 11:51
Artiva Biotherapeutics GAAP EPS of -$0.83
Artiva Biotherapeutics press release (NASDAQ:ARTV): Q1 GAAP EPS of -$0.83. As of March 31, 2025, Artiva had cash, cash equivalents, and investments of $166.0 million which is expected to fund operatio...
05-08 22:22
Artiva Biotherapeutics Q1 EPS $(0.83) Misses $(0.72) Estimate
Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.72) by 15.28 percent.
05-08 20:11
